Human interferon beta ( DrugBank: Human interferon beta, Interferon beta )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	4
26	HTLV-1関連脊髄症	1

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00428584 (ClinicalTrials.gov)	December 2006	29/1/2007	RNF and Betaseron® Tolerability Study	A Randomized, Multicenter, Two Arm, Open Label, Twelve Week Phase IIIb Study to Evaluate the Tolerab ...	Relapsing Remitting Multiple Sclerosis (RRMS)	Drug: New Formulation of rebif - human interferon beta-1a;Drug: Interferon beta -1b	EMD Serono	Pfizer	Completed	18 Years	60 Years	All	129	Phase 3	United States
2	NCT00618527 (ClinicalTrials.gov)	August 2006	6/2/2008	Combination Therapy Using Cellcept and Rebif in RRMS	Combination Therapy Using Mycophenolate Mofetil (CellCept) and Human Interferon beta1a (Rebif) in Ea ...	Multiple Sclerosis	Drug: mycophenolate mofetil (Cellcept);Drug: human interferon beta 1a (Rebif)	Aaron Boster	EMD Serono;Pfizer	Completed	18 Years	65 Years	Both	31	Phase 0	United States
3	EUCTR2004-000337-12-HU (EUCTR)	23/07/2004	29/09/2004	A multicentre, single arm, open-label, phase IV study to evaluate the immunogenicity and safety of s ...	A multicentre, single arm, open-label, phase IV study to evaluate the immunogenicity and safety of s ...	MS with 2 or more relapses within the last 2 years MedDRA version: 7.0;Level: PT;Classification code ...	Trade Name: Rebif Product Name: Rebif Product Code: Not applicable INN or Proposed INN: Interferon beta ...	Serono International SA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	400	Phase 4	Hungary
4	NCT00078338 (ClinicalTrials.gov)	March 2004	23/2/2004	Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis	Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per We ...	Relapsing-remitting Multiple Sclerosis	Drug: Human interferon beta-1a and glatiramer acetate	EMD Serono	Pfizer	Completed	18 Years	60 Years	Both	764	Phase 4	United States;Argentina;Austria;Brazil;France;Germany;Italy;Netherlands;Russian Federation;Spain;Swi ...

First Previous1Next Last

26. HTLV-1関連脊髄症

臨床試験数 : 28 / 薬物数 : 48 - (DrugBank : 28) / 標的遺伝子数 : 38 - 標的パスウェイ数 : 127

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00001785 (ClinicalTrials.gov)	September 1998	3/11/1999	Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated M ...	Combined Virological and Immunological Evaluation of Treatment of Patients With Early HTLV-1-Associa ...	HTLV-I Infection;Spinal Cord Disease;Tropical Spastic Paraparesis	Drug: Recombinant human interferon beta-1a	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	N/A	N/A	Both	12	Phase 2	United States

First Previous1Next Last

先頭へ